Zymeworks Inc. Announces Director Changes and Officer Compensation Details
Ticker: ZYME · Form: 8-K · Filed: Jul 25, 2024 · CIK: 1937653
| Field | Detail |
|---|---|
| Company | Zymeworks INC. (ZYME) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.00001, $485,000, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, officer-compensation, governance
Related Tickers: ZYME
TL;DR
Zymeworks board shakeup: Hastings out, Rosenberg in. Officer pay details also filed.
AI Summary
On July 19, 2024, Zymeworks Inc. filed an 8-K report detailing the departure of Director Dr. Paul Hastings and the appointment of Dr. Steven A. Rosenberg as a new director. The filing also disclosed compensatory arrangements for certain officers, though specific details of these arrangements were not provided in the excerpt.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director departures and changes in executive compensation can indicate internal shifts or strategic realignments that may carry risks.
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- Dr. Paul Hastings (person) — Departing Director
- Dr. Steven A. Rosenberg (person) — Appointed Director
- July 19, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from Zymeworks Inc.'s board of directors?
Dr. Paul Hastings has departed from Zymeworks Inc.'s board of directors as of July 19, 2024.
Who has been appointed as a new director to Zymeworks Inc.'s board?
Dr. Steven A. Rosenberg has been appointed as a new director to Zymeworks Inc.'s board.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is July 19, 2024.
What other information is disclosed in this 8-K filing besides director changes?
The filing also discloses compensatory arrangements of certain officers.
What is Zymeworks Inc.'s state of incorporation and fiscal year end?
Zymeworks Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 2,184 words · 9 min read · ~7 pages · Grade level 12.6 · Accepted 2024-07-25 16:35:01
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
- $485,000 — nd benefits: An annual base salary of $485,000, with eligibility to earn an annual dis
- $50,000 — December 31, 2024. A signing bonus of $50,000 to be paid on the first scheduled pay d
Filing Documents
- d810428d8k.htm (8-K) — 44KB
- d810428dex101.htm (EX-10.1) — 145KB
- d810428dex102.htm (EX-10.2) — 173KB
- d810428dex991.htm (EX-99.1) — 13KB
- g810428dsp36.jpg (GRAPHIC) — 11KB
- 0001193125-24-184871.txt ( ) — 591KB
- zyme-20240719.xsd (EX-101.SCH) — 3KB
- zyme-20240719_lab.xml (EX-101.LAB) — 18KB
- zyme-20240719_pre.xml (EX-101.PRE) — 11KB
- d810428d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: July 25, 2024 By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair, Chief Executive Officer, President and interim Chief Financial Officer 5